Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
MELVILLE, N.Y. - Henry Schein, Inc. (NASDAQ:HSIC), a global provider of health care solutions with a market capitalization of $8.77 billion and annual revenue of $12.67 billion, has finalized a $250 million investment with affiliates of KKR, a prominent investment firm, resulting in KKR acquiring a stake of around 12% in the company. This strategic financial move was completed today, strengthening the relationship between the two entities. According to InvestingPro analysis, the company maintains a "GOOD" financial health score, supported by strong operational metrics.
In conjunction with the investment, Henry Schein has welcomed two new independent directors to its Board. William K. ’Dan’ Daniel, an Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, along with Max Lin, a Partner at KKR who leads the firm’s Health Care industry team in the Americas, have joined the Board of Directors. Lin was appointed on May 2, 2025, and will serve as Vice Chair of the Nominating and Governance Committee, while Daniel will be part of the Compensation Committee. Both will also serve on the Strategic Advisory Committee.
Stanley M. Bergman, Chairman and CEO of Henry Schein, expressed enthusiasm for the new board members, citing their extensive experience in health care and strategic growth as valuable to the company’s BOLD+1 strategy and stakeholder value creation.
Henry Schein, a FORTUNE 500 company and a member of the S&P 500 index, specializes in providing solutions for dental and medical practitioners. With a team of approximately 25,000 members globally, the company supports over 1 million customers with a range of products and services designed to enhance operational success and clinical outcomes.
KKR, known for its alternative asset management and capital markets solutions, brings to the partnership its expertise in health care investments, including dental services, medical products and equipment, and health care software and information technology.
This strategic partnership between Henry Schein and KKR is based on a press release statement and highlights the ongoing collaboration aimed at fostering growth and innovation within the health care solutions sector. For deeper insights into Henry Schein’s valuation and growth prospects, InvestingPro subscribers can access comprehensive analysis, including 7 additional ProTips and a detailed Pro Research Report, part of the platform’s coverage of over 1,400 US equities.
In other recent news, Henry Schein Inc. announced its first-quarter 2025 earnings, revealing a modest earnings per share (EPS) beat with $1.15 compared to the forecasted $1.12. However, the company fell short of revenue expectations, reporting $3.17 billion against the anticipated $3.24 billion. Despite the revenue miss, Henry Schein’s leadership remains optimistic about the future, highlighting strategic initiatives and product innovations. The company’s non-GAAP operating margin improved by 14 basis points to 7.25%, and restructuring efforts resulted in $60 million in cost savings. Additionally, analysts from Stifel noted that foreign exchange volatility continues to impact the company’s revenue. The company anticipates non-GAAP EPS for the remainder of 2025 to be in the range of $4.80 to $4.94, with total sales growth expected between 2% and 4%. In terms of analyst ratings, there were no specific upgrades or downgrades mentioned in the recent reports.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.